Compare JAZZ & CNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | JAZZ | CNA |
|---|---|---|
| Founded | 2003 | 1853 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Property-Casualty Insurers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 12.1B |
| IPO Year | 2007 | 1994 |
| Metric | JAZZ | CNA |
|---|---|---|
| Price | $194.31 | $47.40 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $216.92 | N/A |
| AVG Volume (30 Days) | ★ 734.6K | 321.1K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 8.30% |
| EPS Growth | N/A | ★ 33.24 |
| EPS | N/A | ★ 4.69 |
| Revenue | $1,618,693,000.00 | ★ $14,989,000,000.00 |
| Revenue This Year | $6.13 | N/A |
| Revenue Next Year | $7.75 | N/A |
| P/E Ratio | ★ N/A | $10.09 |
| Revenue Growth | N/A | ★ 5.04 |
| 52 Week Low | $98.96 | $43.29 |
| 52 Week High | $200.24 | $50.72 |
| Indicator | JAZZ | CNA |
|---|---|---|
| Relative Strength Index (RSI) | 61.80 | 54.18 |
| Support Level | $159.78 | $46.75 |
| Resistance Level | $198.00 | $49.86 |
| Average True Range (ATR) | 4.75 | 0.72 |
| MACD | 0.67 | 0.27 |
| Stochastic Oscillator | 69.84 | 77.51 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
CNA Financial Corporation (CNAF) is an insurance holding company that provides commercial property and casualty insurance. The company operates under five segments: Specialty, Commercial and International being its core business, and two segments for its non-core businesses, which are Life and Group and Corporate and Other. CNAF, through its segments, provides professional, financial, specialty property, and casualty products to small businesses and medium-scale organizations. It has its business spread across Continental Europe, United Kingdom, and Canada. The majority of the revenues are generated from the Specialty and Commercial segment of the business.